Publications by authors named "Wayne Shaw"

Claim this Profile
T
Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.
Ulhas Nadgir, Saberi Rana Ali, Jagadish Gogate, Wayne Shaw, José Antunes

Ann Intern Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events.
Muhammad Shahzeb Khan, James L Januzzi, Yuxi Liu, Jialin Xu, Wayne Shaw

J Card Fail· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, Vasilis Tsimihodimos, Fisseha Tesfaye, Wayne Shaw

Diabetes Care· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
Jie Yu, Jingwei Li, Phillip J Leaver, Clare Arnott, Mark D Huffman, Wayne Shaw

Cardiovasc Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
Muthiah Vaduganathan, Naveed Sattar, Jialin Xu, Javed Butler, Kenneth W Mahaffey, Wayne Shaw

J Am Coll Cardiol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
Taha Sen, Jingwei Li, Brendon L Neuen, Clare Arnott, Bruce Neal, Wayne Shaw

J Am Heart Assoc· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
James L Januzzi, Javed Butler, Naveed Sattar, Jialin Xu, Wayne Shaw

Diabetes Care· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
Clare Arnott, Brendon L Neuen, Hiddo J L Heerspink, Gemma A Figtree, Mikhail Kosiborod, Wayne Shaw

Int J Cardiol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
James L Januzzi, Jialin Xu, JingWei Li, Wayne Shaw, Richard Oh

J Am Coll Cardiol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
Toshiaki Ohkuma, Luc Van Gaal, Wayne Shaw, Kenneth W Mahaffey, Dick de Zeeuw

Diabetes Obes Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
JingWei Li, Mark Woodward, Vlado Perkovic, Gemma A Figtree, Hiddo J L Heerspink, Wayne Shaw

JACC Heart Fail· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
Gemma A Figtree, Karin Rådholm, Terrance D Barrett, Vlado Perkovic, Kenneth W Mahaffey, Wayne Shaw

Circulation· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
Zien Zhou, Richard I Lindley, Karin Rådholm, Bronwyn Jenkins, John Watson, Wayne Shaw

Stroke· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw

Lancet Diabetes Endocrinol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Karin Rådholm, Gemma Figtree, Vlado Perkovic, Scott D Solomon, Kenneth W Mahaffey, Wayne Shaw

Circulation· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Wayne Shaw

Circulation· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Wayne Shaw

N Engl J Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw

Diabetes Obes Metab· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Bruce Neal, Vlado Perkovic, David R Matthews, Kenneth W Mahaffey, Greg Fulcher, Wayne Shaw

Diabetes Obes Metab· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies.
Richard E Gilbert, Matthew R Weir, Paola Fioretto, Gordon Law, Mehul Desai, Wayne Shaw

Can J Diabetes· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
Alan J Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Wayne Shaw

J Am Geriatr Soc· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Wayne Shaw

Ann N Y Acad Sci· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
Greg Fulcher, David R Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Wayne Shaw

Diabetes Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Wayne Shaw

Diabetes Care· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Alan Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Cristiana Mayer, Wayne Shaw

BMC Endocr Disord· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis